- PA5-78475 - Invitrogen Antibodies GLS2 antibody

Submitted references Targeting YTHDF1 effectively re-sensitizes cisplatin-resistant colon cancer cells by modulating GLS-mediated glutamine metabolism.

Chen P, Liu XQ, Lin X, Gao LY, Zhang S, Huang X
Molecular therapy oncolytics 2021 Mar 26;20:228-239

Impact of the acidic environment on gene expression and functional parameters of tumors in vitro and in vivo.

Rauschner M, Lange L, Hüsing T, Reime S, Nolze A, Maschek M, Thews O, Riemann A
Journal of experimental & clinical cancer research : CR 2021 Jan 6;40(1):10

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of GLS2 in rat tissue extract using 50 µg of protein. Samples were separated with 10% SDS-PAGE and incubated with GLS2 polyclonal antibody (Product # PA5-78475) using a dilution of 1:1000 followed by HRP-conjugated anti-rabbit IgG.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of GLS2 in mouse tissue extract using 50 µg of protein. Samples were separated with 10% SDS-PAGE and incubated with GLS2 polyclonal antibody (Product # PA5-78475) using a dilution of 1:1000 followed by HRP-conjugated anti-rabbit IgG.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of GLS2 in whole cell lysate using 30 µg of protein. Samples were separated with 10% SDS-PAGE and incubated with GLS2 polyclonal antibody (Product # PA5-78475) using a dilution of 1:1000 followed by HRP-conjugated anti-rabbit IgG.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western Blot using GLS2 Polyclonal Antibody (Product # PA5-78475). Various whole cell extracts (30 µg) were separated by 10% SDS-PAGE, and the membrane was blotted with GLS2 Polyclonal Antibody (Product # PA5-78475) diluted at 1:1,000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western Blot using GLS2 Polyclonal Antibody (Product # PA5-78475). Various tissue extracts (50 µg) were separated by 10% SDS-PAGE, and the membrane was blotted with GLS2 Polyclonal Antibody (Product # PA5-78475) diluted at 1:500. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 2 Change of protein levels of PER3, GLS2, CREM and TXNIP in AT1 prostate and Walker-256 mammary carcinoma cells after 24 h under acidotic (pH 6.6) and/or hypoxic (pO 2 = 1.5 mmHg) conditions. n = 4-12; (*) p < 0.05, (**) p < 0.01 vs. control; ( # ) p < 0.05, ( ## ) p < 0.01 AT1 vs. Walker-256 cells

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 4 Protein levels of PER3, GLS2, CREM and TXNIP in AT1 prostate and Walker-256 mammary carcinoma tumors in vivo 24 h after ( a ) inducing metabolic acidosis by forcing glycolytic metabolism or ( b ) intratumoral injection of lactic acid. n = 4-18; (*) p < 0.05, (**) p < 0.01 vs. control; ( # ) p < 0.05, ( ## ) p < 0.01 AT1 vs. Walker-256 cells

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Cisplatin-resistant CRC cells exhibit elevated glutamine metabolism (A) Heatmap of differentially expressed genes from LoVo parental and CDDP R cells identified by RNA-seq. (B) MetaboAnalyst pathway enrichment analysis of metabolites in LoVo parental and CDDP R cells. (C) mRNA expression levels of glutamine metabolism enzymes and regulators were detected by qRT-PCR in LoVo parental and CDDP R cells. (D) Western blot results show protein expression of GLS1 and GLS2 in LoVo parental and CDDP R cells. (E and F) Glutamine uptake (E) and GLS activity (F) assays were performed in LoVo parental and CDDP R cells. (G) LoVo parental and CDDP R cells were cultured with regular medium or glutamine depletion medium, a clonogenic assay and (H) annexin V assay were performed. (I) LoVo CDDP R cells cultured with regular medium or glutamine depletion medium were treated with cisplatin at 10 and 20 muM for 48 h. (J) Cell viability and cell death were examined by a clonogenic assay and (H) annexin V assay. Columns include mean of three independent experiments; data are presented as mean +- SD. *p < 0.05, **p < 0.01, ***p < 0.001.

PA5-78475

Antibody data